Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study
Abstract Background Gout is the most common inflammatory arthritis. Current urate-lowering therapies have limitations, such as adverse drug reactions or limited efficacy. Epaminurad is a novel selective human urate transporter 1 (hURAT1) inhibitor that has been shown to reduce serum urate (sUA) leve...
Saved in:
| Main Authors: | Jae-Bum Jun, Hye-Soon Lee, Sang-Hyon Kim, Seung-Geun Lee, Doo-Ho Lim, Jinhyun Kim, Yong-Beom Park, Mie Jin Lim, Seung-Jae Hong, Hyo-Jin Choi, Shin-Seok Lee, Hyun Ah Kim, Jiwon Hwang, Chang-Hee Suh, Seungwoo Han, Jung-Yoon Choe, Wan-Hee Yoo, Jung Soo Song |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-025-03577-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Two cases of acute urate nephropathy in women with asymptomatic hyperuricemia
by: L. N. Yeliseyeva, et al.
Published: (2021-03-01) -
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
by: M. N. Chikina
Published: (2019-01-01) -
How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present
by: Robert T. Keenan, et al.
Published: (2024-12-01) -
The beneficial effects of dapagliflozin on the course of experimental urate nephrolithiasis
by: V. Yu. Perfil’ev, et al.
Published: (2017-04-01) -
Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis?
by: Edward Roddy, et al.
Published: (2024-11-01)